Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

CSPC Acquires China Rights to Verastem Cancer Drug in $45 Million Deal

publication date: Sep 26, 2018

CSPC Pharmaceutical in-licensed China rights to an approved cancer treatment, Copitra™, from Verastem, a Boston area biotech. Copitra (duvelisib) is an oral inhibitor of phosphoinositide 3-kinase (PI3K), and the first approved dual inhibitor of PI3K-delta and PI3K-gamma. In the US, Copitra has been approved as a third-line treatment for several leukemia/lymphoma indications. CSPC will make a $15 million upfront payment and pay an additional $30 million in development milestones, plus sales milestones and royalties. More details....

Stock Symbols: (HK: 1093) (NSDQ: VSTM)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China